Did You Know...
...that on Dec. 15, 1836, the Patent Office was completely destroyed by fire? Lost were some 7,000 models, 9,000 drawings, and 230 books plus all records of patent applications and grants.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7285534 | Corticotropin-releasing hormone analogs and their uses This invention provides members of the corticiotropin-releasing hormone superfamily and peptide analogs thereof wherein the 38th amino acid from the N-terminus is D-Nle, i.e. [D-Nle38]-CRH peptide. The peptide analogs can be used to treat proli... | 10/23/2007 |
| 7147856 | Stable radioiodine conjugates and methods of their synthesis Methods are described for conjugating radioiodinated peptides or carbohydrate structures to proteins with improved yields and qualities of conjugates. In one method, specially designed radioiodinated bifunctional peptides containing nonmetabolizable amide bonds are ... | 12/12/2006 |
| 6849600 | Corticotropin-releasing hormone analogs This invention relates to peptide analogs of corticotropin-releasing hormone. Particularly, the invention provides analogs wherein the 38th amino acid from the N-terminus is D-Nle, i.e. [D-Nle38]-CRH peptide. ... | 02/01/2005 |
| 6846803 | Antagonists specific for the corticotropin-releasing factor receptor type 2 (CRFR2) The present invention relates to an antagonist of the ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 8 to 10 N-terminal amino acids of native sauvagine. The present invention also relates to an antagonist of the ligand of the Corti... | 01/25/2005 |
| 6841657 | Inhibitors of HIV membrane fusion Inhibitors of HIV membrane fusion and a method of identifying drugs or agents which inhibit binding of the N-helix coiled-coil and the C helix of HIV gp41 envelope protein. ... | 01/11/2005 |
| 6538106 | Compositions and methods for treating infections using analogues of indolicidin Compositions and methods for treating infections, especially bacterial infections, are provided. Indolicidin peptide analogues containing at least two basic amino acids are prepared. The analogues are administered as modified peptides, preferably containi... | 03/25/2003 |
| 6472369 | Anticancer compounds and methods The testing of tumor cells, including human tumors capable of metastases, in assays employing fibronectin-depleted substrates is described. Ex vivo induction of cells, including biopsied human cells, is performed with invasion-inducing agents. Additionall... | 10/29/2002 |
| 6444645 | Crosslink-stabilized indolicidin analogs The present invention relates to crosslink-stabilized analogs of indolicidin, which is a naturally occurring peptide having the amino acid sequence Ile-Leu-Pro-Trp-Lys-Trp-Pro-Trp-Trp-Pro-Trp-Arg-Arg-CONH2 ("Indol 1-13;" SEQ ID NO: 1). The cros... | 09/03/2002 |
| 6355681 | Glycine substitutes and precursors for treating a psychosis Process for treating psychosis such as schizophrenia using a glycine substitute or a precursor thereof to potentiate NMDA receptormediated neurotransmission.... | 03/12/2002 |
| 6326463 | Cyclic CRF agonists Novel cyclic CRF agonist peptides have the amino acid sequence: (cyclo 30-33)Ac-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala -Arg-Ala-Glu-Gln-Leu-Ala-Gln-Glu-Ala-R32 -R33 -Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2 | 12/04/2001 |
| 6323179 | Chicken GNRH analogs and uses thereof in regulation of fertility and pregnancy Specially designed non-mammalian GnRH analog decapeptides resistant to degradation by the placental enzyme, C-ase-1, or a post-proline peptidase, are disclosed. The GnRH analogs are further defined as analogs of Chicken II GnRH or Salmon GnRH. These non-m... | 11/27/2001 |
| 6180604 | Compositions and methods for treating infections using analogues of indolicidin Compositions and methods for treating infections, especially bacterial infections, are provided. Indolicidin peptide analogues containing at least two basic amino acids are prepared. The analogues are administered as modified peptides, preferably containi... | 01/30/2001 |
| 6103699 | Peptide, a method for its preparation and a pharmaceutical composition containing the peptide A peptide of the formula I X--A--D--Trp--Y wherein X is hydrogen, glycine, alanine, leucine, isoleucine, valine, N-valine, proline, tyrosine, phenylalanine, tryptophan, D-alanine, D-leucine, D-isoleucine, D-valine, D-N-valine, D-proline, D-tyrosine, D-phe... | 08/15/2000 |
| 6051685 | Peptide derivatives A peptide derivative having analgesic activity represented by the following Formula I: ##STR1## wherein Q represents D-Arg or L-Arg; and X represents for example NR6 --CHR7 R8. Typical compounds include H2 ... | 04/18/2000 |
| 6001965 | Anticancer compounds and methods The testing of tumor cells, including human tumors capable of metastases, in assays employing fibronectin-depleted substrates is described. Ex vivo induction of cells, including biopsied human cells, is performed with invasion-inducing agents. Additionall... | 12/14/1999 |
| 5990276 | Synthetic inhibitors of hepatitis C virus NS3 protease An inhibitor of the HCV NS3 protease. The inhibitor is a subsequence of a substrate of the NS3 protease or a subsequence of the NS4A cofactor. Another inhibitor of the present invention contains a subsequence of a substrate linked to a subsequences of the... | 11/23/1999 |
| 5935932 | Bradykinin antagonists containing pentafluorophenylalanine The present invention provides bradykin antagonists containing pentafluorophenylalanine which are therapeutically useful. Moreover, the present invention provides methods to antagonize bradykinin receptors in a mammal in need of such antagonism, comprisin... | 08/10/1999 |
| 5874227 | Cyclic CRF antagonists Novel cyclic CRF antagonist peptides have the amino acid sequence: ##STR1## wherein Y is Ac, H, Ac-Thr or H-Thr; R30 is Glu or Cys; R32 is His or preferably a basic and/or aromatic D-amino acid such as D-His or D-Arg; R33 | 02/23/1999 |
| 5844074 | Cyclic CRF agonists Novel cyclic CRF agonist peptides have the amino acid sequence: (cyclo 30-33)Ac-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu -Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-R30 -Ala-R32 -R33 -Asn-Arg-Lys-Leu-N... | 12/01/1998 |
| 5824771 | Cyclic CRF agonists Novel cyclic CRF agonist peptides have the amino acid sequence: (cyclo 30-33)Ac-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu -Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-R30 -Ala-R32 -R33 -Asn-Arg-Lys-Leu-N... | 10/20/1998 |
| 5777073 | Cyclic CRF antagonist peptides Novel cyclic CRF antagonist peptides are created by shortening the N-terminus of a CRF family peptide by 8-11 residues and adding an acyl group. CML is preferably present in what would be the 27-position of the native CRF sequence, and D-Tyr may be incorp... | 07/07/1998 |
| 5723165 | Aspartyldipeptide derivatives and sweetener compositions containing the same Aspartyldipeptide compounds of the formula (I) L-Asp-X-NH-C*R1 R2 (I) where R1 is alkyl or alkoxymethyl, R2 is phenyl, benzyl, cyclohexyl or cyclohexylmethyl, C* has an (S) configuration when... | 03/03/1998 |
| 5698516 | Biologically active vasopressin analogues Vasopressin analogues of formula (I) ##STR1## wherein X is (S)-2-amino-2-methyl-butanoic acid (CaMeAbu) or Valine (Val), Y is Thienylalanine (Thi) or Methionine (Met), Z is D-Phenylalanine (D-Phe) or D-Thienylalanine (Thi) or D-Tyrosine (D-Tyr), are ... | 12/16/1997 |
| 5663292 | Cyclic CRF analogs Improved CRF antagonist peptides have the formula: ##STR1## wherein R30 is Cys or Glu; R33 is Cys, Lys or Orn; provided that when R30 is Cys, R33 is Cys and when R30 is Glu, R33 is Lys... | 09/02/1997 |
| 5643877 | Compounds comprising gonadotropin releasing hormone (GnRH) and methods for controlling reproduction in fish Novel peptide hormones which influence the release of gonadotropins by the pituitary gland in fish are disclosed. Methods in which such peptides may be administered to fish to control their reproduction are also described. Furthermore, novel isolated cDNA... | 07/01/1997 |
| 5633230 | Treatment of cytomegalovirus infection Described herein are anti-cytomegalovirus peptides. In a preferred embodiment, the peptide is acetyl-[D-Arg]9 -NH2. The use of these peptides, either per se or in combination with other anti-CMV compounds, is disclosed as an effectiv... | 05/27/1997 |
| 5510458 | CRF antagonists Disclosed are improved CRF peptide antagonists such as those having the formula: Y-D-Phe-Xaa13 -Leu-Leu-Arg-Xaa17 -Xaa18 -Leu-Xaa20 -Nle-Xaa22 -Xaa23 -Xaa24 -Xaa25 -Xa... | 04/23/1996 |
| 5487898 | Compositions and method for the sublingual or buccal administration therapeutic agents Pharmaceutical compositions for the sublingual or buccal administration of therapeutic agents which are normally degraded upon oral administration comprise such a therapeutic agent, a solvent, optionally a cosolvent and/or hydrogel, and an oral mucosal me... | 01/30/1996 |
| 5441935 | Growth factor receptors A 75-85 Kd glycopolypeptide, capable of acting as a receptor for polypeptide of the bombesin type, is isolated from the surface of Swiss 3T3 cells. Certain antagonists and antibodies to the glycopolypeptide are described, the antagonists being of quite di... | 08/15/1995 |
| 5439688 | Process for preparing a pharmaceutical composition A pharmaceutical composition is prepared in the form of microparticles or of an implant comprising a biodegradable polymer selected from poly-1,4-butylene succinate, poly-2,3-butylene succinate, poly-1,4-butylene fumarate and poly-2,3-butylene succinate, ... | 08/08/1995 |
| 5262521 | Isolated atrial peptide-degrading enzyme and novel compounds useful as inhibitors thereof A novel atrial peptide-degrading enzyme (ADE) is provided in isolated, purified form. The enzyme has a molecular weight of approximately 160,000 Daltons as measured by gel filtration chromatography, and is effective to cleave atrial peptides such as APII,... | 11/16/1993 |
| 5252718 | Fibroblast growth factor antagonists Antagonists to basic fibroblast growth factor, a 146 amino acid residue polypeptide, are produced. These antagonists are generally between 10 and 45 residues in length and are characterized by their ability to interact with the FGF receptor and/or inhibit... | 10/12/1993 |
| 5250517 | Renin inhibiting compounds Compounds which are amino acid derivatives and have the formula ##STR1## in which R1 is hydrogen or methyl, R2 is ethyl, propyl or imidazol-4-yl, R3 is isobutyl, cyclohexylmethyl or benzyl, and A is defined as herein ... | 10/05/1993 |
| 5248667 | Method of treating psoriasis using synthetic peptide compositions Peptides previously disclosed as useful for preventing HIV from binding to cell binding sites have now been shown to have thymoleptic qualities and to be useful for tretment of psoriasis in patients who lack antibodies against HIV.... | 09/28/1993 |
| 5245009 | CRF antagonists Disclosed are improved CRF peptide antagonists such as those having the formula: Y-D-Phe-R13 -Leu-Leu-Arg-R17 -R18 -Leu-R20 -Nle-R22 -R23 -R24 -R25 -R26 -Leu-R | 09/14/1993 |
| 5235036 | CRF analogs Analogs of CRF, which are based upon hCRF, oCRF and alpha-helical CRF, are disclosed that can be administered to achieve a substantial elevation of ACTH, ଲ-endorphin, ଲ-lipotropin, other products of the pro-opiomelanocortin gene and corticoste... | 08/10/1993 |
| 5232912 | Anticoagulant peptides This invention relates to peptide derivatives which are useful anticoagulant agents.... | 08/03/1993 |
| 5212154 | Preparation for treating complications in diabetes Preparation for preventing or combating complications in diabetes, characterized in that it comprises: (a) insulin or a salt or complex thereof, and (b) a peptide of the general formula I: H-L-Met(X)-L-Glu-L-His-L-Phe-D-Lys-L-Phe-Y or a salt or a N-acyl derivative ... | 05/18/1993 |
| 5190922 | Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands Oligopeptide compounds or oligopeptide analogue compounds of the formula A-B-D-E-G-J-L are ligands for the anaphylatoxin receptor and are useful in the treatment of inflammatory disease states. Also disclosed are anaphylatoxin receptor ligand compositions... | 03/02/1993 |
| 5187156 | Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same The present invention relates to DTrp-Phe containing tripeptides and pharmaceuticals, which possess tachykinin antagonism activity as well as processes of making such peptides.... | 02/16/1993 |
